A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 482
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : TN
Long Form : triple-negative
No. Year Title Co-occurring Abbreviation
2020 Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. BC
2020 Eribulin monotherapy in heavily pretreated metastatic breast cancer patients in real life. MBC, OS
2020 Evaluation of Concordance Between Histopathological, Radiological and Biomolecular Variables in Breast Cancer Neoadjuvant Treatment. BC, HER2, NAC, pCR, PR
2020 GLS2 is protumorigenic in breast cancers. BPTES
2020 The evaluation of the distribution of CD133, CXCR1 and the tumor associated macrophages in different molecular subtypes of breast cancer. HER2OE, LA, LB, TAMs
2020 Triple-Negative Primary Breast Tumors Induce Supportive Premetastatic Changes in the Extracellular Matrix and Soluble Components of the Lung Microenvironment. ECM, EVs, LCM
2019 A role for kinesin-1 subunits KIF5B/KLC1 in regulating epithelial mesenchymal plasticity in breast tumorigenesis. EMP, EMT, KIF5B, KIFs, KLC1, PRL
2019 A systematic review of clinical outcomes and radiotherapy-associated toxicity in multicatheter accelerated partial breast irradiation. CSS, DFS, DMFS, HER2, LR, mAPBI, OS, RNR, RT
2019 Are baseline ultrasound and mammographic features associated with rates of pathological completes response in patients receiving neoadjuvant chemotherapy for breast cancer? NACT, pCR
10  2019 Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident. IR, MPNs
11  2019 Dietary Glycemic Index and Glycemic Load and Risk of Breast Cancer by Molecular Subtype in Mexican Women. BC, ER, GI, GL, HER2, PR
12  2019 Differentiation of triple-negative breast cancer from other subtypes through whole-tumor histogram analysis on multiparametric MR imaging. CI, HER2
13  2019 Does race predict survival for women with invasive breast cancer? DFS, OS
14  2019 Evaluation of MRI accuracy after primary systemic therapy in breast cancer patients considering tumor biology: optimizing the surgical planning. BCS, MRI, pCR, PST
15  2019 Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer. HER2, mRNA, RCB
16  2019 Expression of tumor-associated antigens in breast cancer subtypes. CT, ER, IHC, NY-ESO-1, PgR, PRAME, TAAs
17  2019 Glutamate dehydrogenase (GLUD1) expression in breast cancer. BC
18  2019 HPV DNA Associates With Breast Cancer Malignancy and It Is Transferred to Breast Cancer Stromal Cells by Extracellular Vesicles. BC, EVs, HPV, MS
19  2019 Imaging Cobalamin Uptake within Malignant Breast Tumors In Vivo. Cbl, DEX, ER, HER2, P.I, PC, PR, SPECT, WBP
20  2019 Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer. EEC, IT, MSI, TMB
21  2019 Integrative analyses of triple negative dysregulated transcripts compared with non-triple negative tumors and their functional and molecular interactions. DE, TF
22  2019 Integrative Analysis Reveals Subtype-Specific Regulatory Determinants in Triple Negative Breast Cancer. BC, CNV, CRS, DM, miRNA, TF, YMR
23  2019 Invasive breast cancers in adolescent and young adult women show more aggressive immunohistochemical and clinical features than those in women aged 40-44years. AYA, BCs, DRFS
24  2019 Machine learning for diagnostic ultrasound of triple-negative breast cancer. AUC, CD, ER, GS, HER2, NTN, PR, ROC
25  2019 Machine Learning-Based Analysis of MR Multiparametric Radiomics for the Subtype Classification of Breast Cancer. IHC, LDA, SVM
26  2019 Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. AR, GEA, IHC, MA, PR
27  2019 Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study. BC, IHC, LA
28  2019 Molecular heterogeneity unravelled by single-cell transcriptomics in patients with essential thrombocythaemia. ET, MPN, scRNA-seq
29  2019 Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response. MR, NST
30  2019 Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer. NAC, SLNB
31  2019 Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla. ALND, apCR, HER2, HR, NAC, pCR, SLNB, SLNs
32  2019 Neoadjuvant chemotherapy of capecitabine + epirubicin + cyclophosphamide combination therapy ( 'CEX' therapy) for HER-2 negative breast cancer, as retrospective study in our institute. cCR, CRR, NAC, pCR, PS
33  2019 Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics. IBC, NCDB, OS, pCR
34  2019 Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience. ER, HER2, NACT, pCR
35  2019 Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial. cTnI, DFS, ELISA, HTN, LVEF, MPO, OS, PlGF, VEGF
36  2019 Prognostic Significance of Tumor Subtypes in Women With Breast Cancer According to Stage: A Population-based Study. HER2, HR, OS, TS
37  2019 Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis. BIRC5, DEGs, GEO, GSEA, LAD, OS
38  2019 Radiomic Signatures Derived from Diffusion-Weighted Imaging for the Assessment of Breast Cancer Receptor Status and Molecular Subtypes. ADC, ARM, COM, DWI, HER2, HIS, MRI, RLM, WAV
39  2019 Recurrence in early breast cancer: Analysis of data from 3,765 Australian women treated between 1997 and 2015. EBC, LVI
40  2019 Second-harmonic generation directionality is associated with neoadjuvant chemotherapy response in breast cancer core needle biopsies. F/B, NACT, RCB, SHG
41  2019 Time to Surgery and the Impact of Delay in the Non-Neoadjuvant Setting on Triple-Negative Breast Cancers and Other Phenotypes. HER2, NACT
42  2019 Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings. BRCA, HER2, HP, HRU, MBC, OS, PFS, TNBC
43  2019 Unearthing Regulatory Axes of Breast Cancer circRNAs Networks to Find Novel Targets and Fathom Pivotal Mechanisms. BC, ceRNAs, circRNAs, DECs, MREs, RBPs
44  2018 A Postreconstruction Harmonization Method for Multicenter Radiomic Studies in PET. VOI
45  2018 Alcohol, smoking, and risk of Her2-overexpressing and triple-negative breast cancer relative to estrogen receptor-positive breast cancer. H2E
46  2018 Appearance Constrained Semi-Automatic Segmentation from DCE-MRI is Reproducible and Feasible for Breast Cancer Radiomics: A Feasibility Study. FCM, GC, MSD, RF, VR
47  2018 Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population? AR, BC, PgR
48  2018 Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. PD-L1, TILs
49  2018 ASXL1 mutations in Chinese patients with essential thrombocythemia. ASXL1, CALR, ET, JAK, MPL, PB, PLT, WT
50  2018 Biological Subtypes of Breast Cancer and Sentinel Lymph Node Biopsy. SLN
51  2018 Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer. AC, DRFS, ER, NAC
52  2018 BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia. BC, MLPA, NGS
53  2018 Calein C, a Sesquiterpene Lactone Isolated From Calea Pinnatifida (Asteraceae), Inhibits Mitotic Progression and Induces Apoptosis in MCF-7 Cells. ---
54  2018 Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience. HCT, HMR, MF, MPN, NGS, TAR-SEQ
55  2018 Comparing Accuracy of Mammography and Magnetic Resonance Imaging for Residual Calcified Lesions in Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy. HR, ICC, MMG, MRI, NST
56  2018 Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer. ALK, EGFR, NSCLC, PRS, TKIs, TTR
57  2018 DCE-MRI Pharmacokinetic-Based Phenotyping of Invasive Ductal Carcinoma: A Radiomic Study for Prediction of Histological Outcomes. NTN
58  2018 Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers? DR, DRFS, IFLBC, LRR
59  2018 Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014. CI, HER2, HR, IDC, MBC, OS, SEER
60  2018 Early Breast Cancer in the Elderly: Characteristics, Therapy, and Long-Term Outcome. OS
61  2018 Energy Metabolism Drugs Block Triple Negative Breast Metastatic Cancer Cell Phenotype. OXPHOS
62  2018 Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers. CTAs
63  2018 Expression of p27 and c-Myc by immunohistochemistry in breast ductal cancers in African American women. AA, BC, IHC, TMAs, TNBC
64  2018 Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer. BC, BM, ER, HR, PR
65  2018 Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters. ER, HER2, NAC, pCR, ROC, tHb
66  2018 IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages. HP, IBC, IL-10, pro-CPB2, RFLP, TM
67  2018 Immune characterization of breast cancer metastases: prognostic implications. BC, OS, TILs
68  2018 Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study. NAC, pCR, VD
69  2018 Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer. CBR, MBC, ORR, OS, PFS
70  2018 Menopausal Status and Outcomes of BRCA Mutation Carriers with Breast Cancer. BC, BRCAm, Post-M, Pre-M
71  2018 Mutant p53 in breast cancer: potential as a therapeutic target and biomarker. ---
72  2018 Nipple-Sparing Mastectomy is Not Associated with a Delay of Adjuvant Treatment. CT, NSM, pCR, SSM
73  2018 Outcomes research examining treatments, quality of life and costs in HER2-negative and triple-negative metastatic breast cancer: a systematic literature review. CER, MBC, QOL
74  2018 Over expressing miR-19b-1 suppress breast cancer growth by inhibiting tumor microenvironment induced angiogenesis. HUVECs
75  2018 Phosphatidylserine-exposing blood and endothelial cells contribute to the hypercoagulable state in essential thrombocythemia patients. ECs, ET, PS
76  2018 Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer. NLR, PLR
77  2018 Prediction of pathological response to neoadjuvant chemotherapy in breast cancer patients by imaging. Lum, NAC, pCR
78  2018 Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy. FAC, NCT, pCR
79  2018 Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma. cCR, NAC, pCR
80  2018 pSTAT3/pSTAT5 Signaling Patterns in Molecularly Defined Subsets of Myeloproliferative Neoplasms. MPNs
81  2018 Quantitative analysis of peri-tumor fat in different molecular subtypes of breast cancer. HER2, HR
82  2018 Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. NC, OS, pCR
83  2018 Role of 18F-PET/CT in Predicting Prognosis of Patients With Breast Cancer After Neoadjuvant Chemotherapy. FDG, NAC, pCR, PET/CT
84  2018 Single drug biomarker prediction for ER- breast cancer outcome from chemotherapy. ---
85  2018 Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BC, HER2, miRNA, pCR
86  2018 Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database. DCIS, ER, HER2, HR, PR
87  2018 Texture analysis of high-resolution dedicated breast 18 F-FDG PET images correlates with immunohistochemical factors and subtype of breast cancer. HER2pnl, LA, MATV, TF, TLG
88  2018 The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. BC, HER2, METABRIC, TMA
89  2018 The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. DFS, HR, IBC, pCR
90  2018 The efficacy and feasibility of dose-dense sequential chemotherapy for Japanese patients with breast cancer. DDCT, G-CSF, pCR, RDI
91  2018 The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients. DFS, ER, LABC, NACT, OS, pCR, PgR
92  2018 The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes. BC, NPI, SLC3A2, TMA
93  2018 The Obesity and the Risk of Breast Cancer among Pre and Postmenopausal Women ER
94  2018 TIMP3 Promoter Methylation Represents an Epigenetic Marker of BRCA1ness Breast Cancer Tumours. BC, MLPA, MS
95  2018 Total choline quantification measured by 1H MR spectroscopy as early predictor of response after neoadjuvant treatment for locally advanced breast cancer: The impact of immunohistochemical status. ANOVA, AUC, pCR, ROC, tCho
96  2018 Transforming growth factor beta 1 (TGFbeta1) polymorphisms and haplotype structures have dual roles in breast cancer pathogenesis. BC, SNPs, TGF-beta1
97  2018 Treatment Strategies in Octogenarians with Early-Stage, High-Risk Breast Cancer. ---
98  2018 Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile. DCIS, IHC
99  2018 Triple-negative and HER2-overexpressing breast cancer cell sialylation impacts tumor microenvironment T-lymphocyte subset recruitment: a possible mechanism of tumor escape. CTL/NK, HER2, LUM, TIL
100  2018 Triple-negative invasive breast carcinoma: the association between the sonographic appearances with clinicopathological feature. HER2